Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| N° IDRCB : 2025-A00757-42 | Other Identifier | ANSM |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Cerebral arteriovenous malformations (CAVMs) are abnormal vessels located on the surface of the brain or within the cerebral parenchyma, causing abnormal communication between the arterial and venous networks, without the interposition of the capillary bed. The main risk associated with these malformations is rupture, which causes intracranial bleeding and can lead to serious sequelae or even death. CAVMs (except those of clearly identified genetic origin [< 5%], such as mutations associated with Rendu-Osler disease) have long been considered to be of non-genetic origin.
However, somatic genetic mutations that activate the RAS/RAF/MEK/ERK (MAPK) signalling pathway have recently been identified in surgical specimens of cAVMs. Furthermore, targeted inhibition of this pathway is effective in treating these malformations in animals and appears to be effective in extracranial arteriovenous malformations, particularly superficial ones.
Next-generation sequencing of circulating DNA in liquid biopsies is a promising new and minimally invasive approach for studying the presence of mutations in arteriovenous malformations.
The goal of treating a cAVM is to obliterate the malformation in order to prevent or avoid the risk of haemorrhage. Several therapeutic modalities may be used, which can be combined: microsurgery, endovascular embolisation, and/or radiosurgery. However, these are invasive treatments that are not without risk.
The detection of mutations by liquid biopsies would enable the development of targeted, non-invasive drug therapies against these cAVMs.
The population consists of patients aged 18 years or older with cAVMs, for whom treatment by venous embolisation was recommended during a multidisciplinary consultation meeting.
This research focuses on identifying somatic genetic mutations that activate the RAS/RAF/MEK/ERK (MAPK) signalling pathway in cAVMs. These mutations have already been identified in surgical specimens. This research aims to evaluate the genetic mutations identified by liquid biopsies on the drainage vein of cAVMs and the prevalence of each mutation.
These liquid biopsies will be performed during embolisation surgery by sampling the drainage vein of the malformation and peripheral venous blood (no additional procedures compared to usual care).
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Search for activating somatic genetic mutations | Other | This research aims to evaluate the genetic mutations identified by liquid biopsies on the drainage vein of AVMs, and the prevalence of each mutation. These liquid biopsies will be performed during the embolisation procedure by sampling the drainage vein of the malformation and peripheral venous blood (no additional procedures compared to standard care). |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluate genetic mutations identified by liquid biopsies on the drainage vein of AVMs. | determination of each mutation identified in the drainage vein of AVMs, | Embolisation procedure (D0), i.e. a maximum of 45 days after the patient has agreed to participate |
| Assessment of the prevalence of each mutation identified by liquid biopsies on the drainage vein of AVMs | Evaluation of the prevalence of each mutation identified in the drainage vein of AVMs, with calculation of the exact 95% confidence interval. | Embolisation procedure (D0), i.e. a maximum of 45 days after the patient has agreed to participate |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of the imaging characteristics of cAVMs for each of the mutations identified. | Imaging characterisation of cAVMs for each of the mutations identified | Embolisation procedure (D0), i.e. a maximum of 45 days after the patient has agreed to participate |
| Evaluate genetic mutations identified by liquid biopsies on the peripheral vein of AVMs. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
The population consists of patients aged 18 years or older with cAVMs, for whom treatment by venous embolisation was recommended during a multidisciplinary consultation meeting.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Julien JB BUREL, Doctor | Contact | 02 32 88 88 50 | +33 | Julien.Burel@chu-rouen.fr |
| Vincent VF FERRANTI, ARC | Contact | 02 32 88 82 65 | +33 | Vincent.Ferranti@chu-rouen.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital of Caen | Caen | 14033 | France |
The data provided will be the property of the sponsor and will be used solely for its own research activities.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002538 | Intracranial Arteriovenous Malformations |
| ID | Term |
|---|---|
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Whole blood drawn from a peripheral vein at the start and end of embolisation via the venous catheter used by the anaesthesia team as part of routine care for Research into somatic genetic mutations that activate the RAS/RAF/MEK/ERK (MAPK) signalling pathway in cAVMs
determination of each mutation identified in the peripheral vein of AVMs |
| Embolisation procedure (D0), i.e. a maximum of 45 days after the patient has agreed to participate |
| Assessment of the prevalence of each mutation identified by liquid biopsies on the peripheral vein of AVMs | Evaluation of the prevalence of each mutation identified in the peripheral vein of AVMs, with calculation of the exact 95% confidence interval. | Embolisation procedure (D0), i.e. a maximum of 45 days after the patient has agreed to participate |
| Hôpital la Pitié-Salpêtrière | Paris | 75013 | France |
|
| University Hospital of Rouen | Rouen | 76031 | France |
|
| D020785 | Central Nervous System Vascular Malformations |
| D009421 | Nervous System Malformations |
| D001165 | Arteriovenous Malformations |
| D054079 | Vascular Malformations |
| D018376 | Cardiovascular Abnormalities |
| D002318 | Cardiovascular Diseases |
| D014652 | Vascular Diseases |
| D020765 | Intracranial Arterial Diseases |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |